DNA Wellness Secures Exclusive Rights for DNA Ploidy Test to Combat Cervical Cancer
Jan Hitaishi
3 min read
Ahmedabad, September 11, 2024: DNA Wellness India Private Limited (DNA Wellness) on Tuesday announced the acquisition of exclusive rights to carry out the DNA Ploidy Test, a groundbreaking diagnostic tool developed by the British Columbia Cancer Research Agency, Canada. The test, also known by the brand name, CERViSure, is a quick, accurate, and non-invasive method to detect cervical cancer. Alongside, the company also launched India’s first CERViSure laboratory in Ahmedabad, Gujarat, which will provide easy access to cervical cancer screening to people here. Priced at Rs 5,500, the test is an essential tool for cervical cancer prevention.
Founded in November 2020 and headquartered in Ahmedabad, Gujarat, DNA Wellness is a leading player in providing advanced DNA profiling technologies in India. It works in the area of detecting genetic instability to improve patient outcomes for screening of diseases. With a focused mission of achieving a ‘Cervical Cancer-Free India’, the company has introduced the DNA Ploidy Test under the brand name CERViSure test to the Indian market, through the invention of British Columbia Cancer Research Agency, Canada.
A major breakthrough in cervical cancer detection, CERViSure test can help identify cancerous cells, about two years before conventional methods. The test also comes with greater accuracy with 100% specificity and 98% sensitivity.
Commenting on the launch of CERViSure,Pathik Bhandari, Co-founder, DNA Wellness, said, “The launch of the DNA Ploidy Test in India is our first step in the direction of realising our vision of a Cervical Cancer-free India. This will empower women across India by giving them access to early detection, thus, improving survival rates of affected patients. Starting with our home market of Gujarat, we will be establishing our dedicated laboratories across India to ensure the widest reach of CERViSure.”
“Going forward, DNA wellness will invest Rs 200 crore to set up some 100 dedicated CERViSure laboratories across India, in a phased manner by 2027, to help the DNA Ploidy reach a maximum number of patients. By October 2024, the company will open dedicated laboratories in Ahmedabad, Vadodara, Rajkot and Surat,” Bhandari further went on to say.
This will be followed by strategic expansions in other Indian states. DNA Wellness plans to collaborate with hospitals, clinics, and doctors to expand access to the DNA Ploidy Test, aiming to make it available nationwide.
Dr Anjana Chauhan,GynecOncologist, said, “Cervical cancer remains one of the most prevalent cancers among women in India, yet it is also one of the most preventable ones. Early detection is critical to saving lives, and the introduction of the DNA Ploidy Test as part of the CERViSure initiative is a significant advancement. With its high sensitivity and specificity, this test enables us to detect precancerous changes long before they develop into cervical cancer, giving women the opportunity for timely intervention and thus prevention. As we see rising incidences of cervical cancer, such innovations go a long way in improving outcomes and moving us closer to a future where no woman has to face this disease unchecked.”
About DNA Wellness India Private Limited:
Founded in November 2020, DNA Wellness India Private Limited is a leading player in providing advanced DNA profiling technologies, focusing on the early detection and prevention of cervical cancer. Headquartered in Ahmedabad, Gujarat, the company aims to revolutionise cancer care in India through innovative screening solutions. Having recently acquired a highly efficient, quick and accurate technology for cervical cancer screening, the company is in the process of launching dedicated testing laboratories in Ahmedabad, Vadodara, Surat, Rajkot and Mumbai by end of 2024. With ambitious expansion plans across the country, the company will also explore screenings for oral, ovarian, prostate, and colon cancers.
